Innovation Sprint Partners with Agostino Gemelli
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Innovation Sprint Partners with Agostino Gemelli

By Pharma Tech Outlook | Friday, October 30, 2020

Mr. Sofoklis Kyriazakos, CEO

Innovation Sprint and Fondazione Policlinico Universitario Agostino Gemelli join forces to conduct AI-powered oncology clinical trial.

FREMONT, CA: Innovation Sprint, a Belgian digital biotech company partners with Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy, co-sponsoring the clinical trial APACHE: Advanced patient monitoring and A.I. supported outcomes evaluations in cervical cancer using Internet of things technologies, involving both the Gemelli advanced radiotherapy center and the gynecology department.

This 24 months trial's primary objective is to assess whether monitoring oncological patients during multimodal cancer therapies may represent a significant step towards a comprehensive and reliable quality of life evaluation, prevention of toxicity before its clinical onset, and treatment outcomes prediction.

Innovation Sprint has deployed its eClinical solution Healthentia in APACHE to allow a seamless ePRO/eCOA collection of reported outcomes and assessment of physical activity, emotional, and lifestyle status of patients undergoing cancer therapy as secondary objectives are to compare patient-reported outcomes with corresponding clinical records about early and late toxicity, instrumental activities of daily living (iADLs), and stress/coping levels and be able to profile patients based on their scores and activity. More specifically, the project evaluates patients' Quality of Life using portable monitoring technologies during the multimodal oncological therapies for cervical cancer, paving the way to develop new Personalized Medicine paradigms for gynecological and radiation oncology. This will be done through training models using advanced A.I. solutions and Machine Learning on the patients-reported and monitored data creating composite lifestyle biomarkers.

Innovation Sprint has raised funding from Innoviris in Belgium to validate the development of the Healthentia AI component to discover lifestyle composite biomarkers that can be used to associate certain patient phenotypes with clinical outcomes. The funded project "Deep Learning of Patients" will be validated in the APACHE clinical trial. Healthentia will monitor cervical cancer patients using a novel composite biomarker defined from RWD by Innovation Sprint. The use of this novel biomarker will enable investigators to predict the disease state and the associated clinical outcomes. At the same time, Innovation Sprint claims that this is the first step towards delivering Digital Therapeutic Services (DTx), processing Real World Data to provide personalized interventions of high efficacy under a strict clinical framework.

Weekly Brief

Read Also